[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431902":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":10,"locations":22,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Lund University Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with Mycosis fungoides and Sézary syndrome",null,[12],"Diagnostic Test: Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.",{"label":14,"type":10,"description":10,"interventionNames":15},"Healthy volontaires",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.","The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.",[14,9],[23],{"facility":5,"status":24,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Lund","SE-221 85","Sweden","SE",{"type":30,"coordinates":31},"Point",[32,33],13.19321,55.70584,{"lat":33,"lon":32},[36,41,45],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Kristina Drott, MD, PhD","CONTACT","+46 46 17 75 20","kristina.drott@med.lu.se",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Jan Sundberg, RN","+46 46 17 70 34","jan.sundberg@skane.se",{"name":37,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100431902","predictive-and-prognostic-biomarkers-in-patients-with-mycosis-fungoides-and-szary-syndrome-100431902",false,"NCT04904146","Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.","BIO-MUSE","Inclusion Criteria:\n\n* Age 18-100 years\n* Histologically confirmed (according to the World Health Organization (WHO)\u002FEORTC classification) MF\u002FSS stages I-IV\n* WHO performance status 0 -3\n* Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.\n* Written informed consent according to International Conference on Harmonization (ICH)\u002F(Good Clinical Practice (GCP), and Swedish regulations\n* No minimum or maximum required routine laboratory data\n\nExclusion Criteria:\n\nNot applicable. No exclusion criteria are specified.",true,"ALL","18 Years","100 Years",{"count":61,"type":62},120,"ESTIMATED","OBSERVATIONAL","A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.",[66,67],"Mycosis Fungoides","Sezary Syndrome",[69,70,71,72,73,74,75,76,77],"Skin lymphoma","Mycosis fungoides","Sezary syndrome","Translational research","Biomarkers","Treatment prediction","Lymphoma microenvironment","Skin neoplasms","Treatment","2025-03-05",{"date":80,"type":81},"2025-03-10","ACTUAL",{"date":83,"type":81},"2021-04-02",{"date":85,"type":62},"2027-04",{"name":5,"class":6},1]